NCT05631444View on ClinicalTrials.gov

Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

October 28, 2022

Conditions
Chronic Limb-threatening IschemiaDiabetes Mellitus
Interventions
BIOLOGICAL

Cell-based therapy

One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.

Trial Locations (1)

Unknown

Fundación Oftalmológica de Santander (FOSCAL), Bucaramanga

All Listed Sponsors
lead

Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

OTHER

NCT05631444 - Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia | Biotech Hunter | Biotech Hunter